India's economic engine is revving up, but navigating the global headwinds requires sharp strategy. The rupee's recent volatility against the dollar underscores the complexities facing Indian businesses, impacting everything from import-export trade to domestic inflation. This week alone, we've seen significant shifts in the IT sector, with major players announcing restructuring and a renewed focus on AI-driven solutions. Meanwhile, the burgeoning startup ecosystem continues to attract substantial funding, despite a cautious global investor sentiment. The government's recent policy announcements on infrastructure development and digitalization are poised to further shape the business landscape, creating both opportunities and challenges for entrepreneurs and established corporations alike. Understanding these market dynamics is crucial for success in today's rapidly evolving Indian economy. Stay informed with Abtak.com for the latest insights and analysis on key sectors including finance, manufacturing, and technology – empowering your business decisions in a dynamic market. Explore the complete business news section now to stay ahead of the curve.
Dr Reddy's Laboratories has received a report from the US Food and Drug Administration. The report concerns its manufacturing facility in Srikakulam, Andhra Pradesh. The USFDA has classified the inspection outcome as Voluntary Action Indicated. This means the inspection is officially closed. The company received the Establishment Inspection Report on October 20, 2025. Drugmaker Dr Reddy's Laboratories Ltd on Tuesday said it has received establishment inspection report from the US health regulato
Granules Life Sciences (GLS) manufacturing facility in Shamirpet, near Hyderabad, has been classified as voluntary action indicated (VAI) by the U.S. Food and Drug Administration (U.S. FDA) consequent to an inspection in December 2025. The establishment inspection report (EIR) was issued following a current good manufacturing practice (cGMP) and pre-approval inspection (PAI) of the oral solid dosage manufacturing operations between December 15 and 19. The inspection is now closed and no regulato ...Read More >
Indian markets saw gains on Friday. Britannia Industries is focusing on localized strategies. Hyundai aims for growth through domestic sales and exports. Alembic Pharma received US FDA EIR. Diamond Power secured a Rs 236 crore order from Adani Energy. GMR Airports reported a passenger traffic decline. RailTel received a Rs 209 crore order. Markets extended their winning streak on Friday, gaining nearly half a percent, in line with favorable global and domestic cues. In today's trade, shares of G ...Read More >
(RTTNews) - Indian shares were moving lower on Monday amid concerns over persistent selling by FIIs and renewed uncertainty around U.S.-India trade negotiations. Global sentiment also remains fragile as investors continue to reduce exposure to tech stocks on valuation concerns. The benchmark BSE Sensex was down 320 points, or 0.4 percent, at 84,946 in early trade, while the broader NSE Nifty index dipped 105 points, or 0.4 percent, to 25,941. Among the prominent decliners, TMPV, Power Grid Corp, Bajaj FinServ and Mahindra & Mahindra fell 1-2 percent. Dr Reddy's Laboratories fell about 1 pe ...Read More >
Glenmark Pharmaceuticals disclosed receiving a warning letter from the U.S. FDA for its Indore facility following a February inspection. The company clarified that the letter won't impact existing supplies or revenues. It also emphasized its commitment to compliance and noted no data integrity issues were found. Glenmark Pharmaceuticals shares may be in focus on Monday, July 14, after the company disclosed that it has received a warning letter from the U.S. Food and Drug Administration (FDA) for ...Read More >
Lords Mark Industries Ltd. secures US FDA Registration, Reinforces India's Position in Global Healthcare Manufacturing . 4 min read Last Updated : Oct 13 2025 | 1:16 PM IST Mumbai, October 11, 2025: Lords Mark Industries Ltd., has received US FDA registration for its range of surgical consumables, orthopedic supports, and hygiene products -- a milestone that reinforces its manufacturing excellence and strengthens India's position in the global healthcare supply chain. US FDA registration repr ...Read More >
First & only immuno-oncology drug approved by various regulatory authorities around the world Dr. Reddy's Laboratories has announced the launch of Toripalimab in India. Toripalimab is a New Biological Entity (NBE). It is the only immuno-oncology drug approved by various regulatory authorities around the world such as United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In 2023, Dr. Reddy's entered in ...Read More >
Granules India shares slipped sharply in trade, down nearly 10% after the company informed that US FDA has classified the inspection at Gagillapur facility in Hyderabad, Telangana as an 'Official Action Indicated' (OAI). The exchanges were informed about an inspection at the facility on September 7, which had resulted in a Form 483 issuance with six observations. Now, Granules India has said that it has responded to 'all the observations' issued by the USFDA. "The Company has responded to all the observations issued by the US FDA. Additionally, the Company has voluntarily undertaken a compr ...Read More >
Hyderabad : Granules India Limited today announced that its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), has concluded a recent US FDA inspection of its manufacturing facility at Shamirpet, Telangana, with an inspection classification of Voluntary Action Indicated (VAI). The Establishment Inspection Report (EIR) was issued following a current Good Manufacturing Practice (cGMP) and pre approval inspection (PAI) of the oral solid dosage manufacturing operations conducted between December 15 and 19, 2025. The inspection is now closed, and no regulatory action has been ...Read More >
New Delhi, September 15: Dalal Street is expected to see selective stock action on Monday, September 15, as several companies announced key updates over the weekend. Market sentiment may remain stock-specific, with developments spanning acquisitions, order wins, regulatory observations, and fundraising plans. Investors are likely to track healthcare, infrastructure, and power sector plays closely, alongside midcaps riding on new contracts. Global cues and domestic macro trends will set the broader tone, but these individual stocks could see heightened activity based on fresh news flow. Trader ...Read More >